-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on CytomX Therapeutics, Raises Price Target to $12

Benzinga·11/06/2026 16:51:29
Listen to the news
Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and raises the price target from $11 to $12.